Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDT in Refractory Mycosis Fungoides
NCT03281811Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Nov 2017
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aminolevulinic acid in mycosis fungoides (MF), sponsored by Mayo Clinic. Primary endpoint: Complete clinical response at 24 weeks. Started Nov 2017; status: completed.
02
Drugs
aminolevulinic acid
03
Conditions
mycosis fungoides (MF)
Beyond the preview
Go deeper on NCT03281811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03281811.